{"nctId":"NCT02584504","briefTitle":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","startDateStruct":{"date":"2015-11-30","type":"ACTUAL"},"conditions":["Hypercholesterolemia"],"count":163,"armGroups":[{"label":"Alirocumab 150 mg Q4W","type":"EXPERIMENTAL","interventionNames":["Drug: Alirocumab","Drug: Placebo","Drug: Atorvastatin","Drug: Non-statin Lipid-Modifying Therapy","Other: Diet Alone"]},{"label":"Alirocumab 150 mg Q2W","type":"EXPERIMENTAL","interventionNames":["Drug: Alirocumab","Drug: Atorvastatin","Drug: Non-statin Lipid-Modifying Therapy","Other: Diet Alone"]},{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Atorvastatin","Drug: Non-statin Lipid-Modifying Therapy","Other: Diet Alone"]}],"interventions":[{"name":"Alirocumab","otherNames":["SAR236553","REGN727"]},{"name":"Placebo","otherNames":[]},{"name":"Atorvastatin","otherNames":[]},{"name":"Non-statin Lipid-Modifying Therapy","otherNames":[]},{"name":"Diet Alone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria :\n\nParticipants with hypercholesterolemia (heFH or non-FH) receiving non statin LMTs or the lowest strength of statin.\n\nExclusion criteria:\n\n* LDL-C \\<100 mg/dL (\\<2.59 mmol/L) at the screening visit (Week -3) in participants with heFH or in participants with non-FH who have a history of documented coronary heart disease.\n* LDL-C \\<120 mg/dL (\\<3.10 mmol/L) at the screening visit (Week -3) in participants with non-FH participants who had a history of documented diseases or other risk factors classified as primary prevention category III as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.\n* Not on a stable dose of LMT (including diet therapy alone) in the run-in period or the screening period.\n* Fasting serum TGs \\>400 mg/dL (\\>4.52 mmol/L) at the screening period.\n* Systolic blood pressure (BP) \\>160 mmHg or diastolic BP \\>100 mmHg at the run-in visit (Week -7) or the screening visit (Week -3) or the randomization visit (Week 0).\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis","description":"Adjusted Least-squares (LS) means and standard errors at Week 12 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were used in the model (ITT analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.8","spread":"2.2"},{"groupId":"OG001","value":"-70.1","spread":"2.3"},{"groupId":"OG002","value":"-4.3","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12- On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.4","spread":"2.1"},{"groupId":"OG001","value":"-70.1","spread":"2.2"},{"groupId":"OG002","value":"-2.8","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12: ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment and assigning a weight of 0.5 for Week 10 and 12 time points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.2","spread":"1.9"},{"groupId":"OG001","value":"-69.9","spread":"1.9"},{"groupId":"OG002","value":"-3.7","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12- On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection) and assigning a weight of 0.5 for Week 10 and 12 time points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.0","spread":"1.9"},{"groupId":"OG001","value":"-69.9","spread":"1.9"},{"groupId":"OG002","value":"-2.6","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 12: ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.2","spread":"2.0"},{"groupId":"OG001","value":"-57.9","spread":"2.0"},{"groupId":"OG002","value":"-6.0","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo-B at Week 12- On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data at from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.8","spread":"2.0"},{"groupId":"OG001","value":"-58.0","spread":"2.0"},{"groupId":"OG002","value":"-4.6","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12: ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.2","spread":"2.0"},{"groupId":"OG001","value":"-61.1","spread":"2.0"},{"groupId":"OG002","value":"-4.9","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 12- On-treatment Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.9","spread":"1.9"},{"groupId":"OG001","value":"-61.1","spread":"2.0"},{"groupId":"OG002","value":"-3.5","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12- ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.8","spread":"1.5"},{"groupId":"OG001","value":"-44.7","spread":"1.6"},{"groupId":"OG002","value":"-3.3","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- ITT Analysis","description":"Calculated LDL-C goal was defined as calculated LDL-C \\<100 mg/dL (2.59 mmol/L) for heterozygous familiar hypercholesterolemia (heFH) participants or non-familial hypercholesterolemia (non-FH) participants who had a history of documented CHD, or \\<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 12 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were included in the imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.2","spread":null},{"groupId":"OG001","value":"96.2","spread":null},{"groupId":"OG002","value":"14.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- On-Treatment Analysis","description":"Calculated LDL-C goal was defined as calculated LDL-C \\<100 mg/dL (2.59 mmol/L) for heFH participants or non-FH participants who had a history of documented CHD, or \\<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 12 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.2","spread":null},{"groupId":"OG001","value":"96.2","spread":null},{"groupId":"OG002","value":"10.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis","description":"Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were included in the imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.7","spread":"3.3"},{"groupId":"OG001","value":"-49.6","spread":"3.3"},{"groupId":"OG002","value":"1.3","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12- ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"1.8"},{"groupId":"OG001","value":"9.9","spread":"1.8"},{"groupId":"OG002","value":"2.0","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides (TGs) at Week 12: ITT Analysis","description":"Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"3.7"},{"groupId":"OG001","value":"-18.0","spread":"3.8"},{"groupId":"OG002","value":"-6.4","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 12: ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"1.6"},{"groupId":"OG001","value":"9.1","spread":"1.7"},{"groupId":"OG002","value":"2.9","spread":"1.6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Calculated LDL-C at Week 20, 24, 36, 48 and 64 -OLTP Analysis","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.1","spread":"20.1"},{"groupId":"OG001","value":"-47.8","spread":"24.2"},{"groupId":"OG002","value":"-45.5","spread":"20.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.7","spread":"20.4"},{"groupId":"OG001","value":"-46.0","spread":"20.0"},{"groupId":"OG002","value":"-47.8","spread":"21.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.2","spread":"19.4"},{"groupId":"OG001","value":"-51.5","spread":"19.6"},{"groupId":"OG002","value":"-56.2","spread":"18.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.6","spread":"21.6"},{"groupId":"OG001","value":"-53.9","spread":"17.6"},{"groupId":"OG002","value":"-57.8","spread":"17.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.3","spread":"22.8"},{"groupId":"OG001","value":"-55.2","spread":"17.5"},{"groupId":"OG002","value":"-58.1","spread":"19.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":56},"commonTop":["Viral upper respiratory tract infection","Fall","Back pain","Pharyngitis","Non-cardiac chest pain"]}}}